Cepheid Logo
Request Info
Location / Language

{{headingText}}

{{paragraphText}}

{{continueBtnLabel}}
{{initials}}
Main Menu
Location / Language

{{headingText}}

{{paragraphText}}

{{continueBtnLabel}}

Request Info
Request Info

Xpert® Xpress CoV-2 plus

Order & Support
CoV-2 plus (FDA cleared) computer generated depiction.
Designed with 3 gene targets for a rapid, robust detection of SARS-CoV-2

The Need

an ill woman listens to a physician
  • SARS-CoV-2 infections are associated with increased morbidity, mortality, cost and pose an ever-present threat to public health globally.1,2
  • SARS-CoV-2 variants continue to emerge, resulting in the risk of new surge cases and death.2
  • Testing required to identify the breakthrough infections and informing patient care, especially for the high-risk population.3
1 WHO Coronavirus (COVID-19) Dashboard – Last accessed 22nd Sep 2023
2 https://news.un.org/en/story/2023/05/1136367
3 Peeling RW, Heymann DL, Teo YY, Garcia PJ. Diagnostics for COVID-19: moving from pandemic response to control. Lancet. 2022 Feb 19;399(10326):757-768. doi: 10.1016/
S0140-6736(21)02346-1. Epub 2021 Dec 20. PMID: 34942102; PMCID: PMC8687671

The Solution

a male and a female researchers scanning cepheid test cartridges
The Xpert Xpress CoV-2 plus test is a rapid, real-time PCR test intended for the qualitative detection of nucleic acid from SARS-CoV-2 in nasopharyngeal swab or anterior nasal swab specimens from individuals suspected of COVID-19 by their healthcare provider, as well as anterior nasal swab specimens from any individual, including from individuals without symptoms or other reasons to suspect COVID-19
The Xpert Xpress CoV-2 plus test provides:
  • Fast and accurate results in as early as 20 minutes*
  • Three gene targets for the detection of SARS-CoV-2, providing target redundancy to mitigate potential impact of genetic mutation
  • Rapid sample-to-answer testing with actionable results and minimal hands-on-time
* With early assay termination for positives, otherwise, the full test runtime is 30 minutes.
CE-IVD. In Vitro Diagnostic Medical Device. May not be available in all countries

The Impact

a smiling female doctor attends an elderly woman
  • Support clinicians with broader coverage for SARS-CoV-2 variants with a three-gene target design.
  • Rapid PCR workflows can reduce time to result, isolation times, and total costs while optimizing capacity. 5
  • Enable patients to receive timely and appropriate treatment.4
4 Shah MM, Joyce B, Plumb ID, et al. Paxlovid Associated with Decreased Hospitalization Rate Among Adults with COVID-19 — United States, April–September 2022. MMWR Morb Mortal Wkly Rep 2022;71:1531–1537.
5 Fistera D, Kikull K, Risse J, Herrmann A, Brachmann M, Kill C. Point-of-care PCR testing of SARS-CoV-2 in the emergency department: Influence on workflow and efficiency. PLoS One. 2023 Aug 3;18(8) https://pubmed.ncbi.nlm.nih.gov/37535577

Connect To Better Outcomes

Request Info

Insights

Get More Insights